ALUR Share Price Performance
US$1.39
-10.05 (-87.85%)
76.2% undervalued intrinsic discount
US$5.83
Fair Value
Price US$1.39
AnalystConsensusTarget US$5.83
AnalystHighTarget US$16.00
AnalystLowTarget US$2.50
Fair ValueUS$7.00
Share Pricen/a
Allurion Technologies Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
ALUR Community Narratives
AN
Fair Value US$7 n/aintrinsic discount
Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value US$16 91.3% undervalued intrinsic discount
Global Obesity Trends And Telemedicine Will Accelerate Non-invasive Weight Loss
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$2.5 44.4% undervalued intrinsic discount
Distributor Disruptions And FDA Delays Will Permit Modest Rebound
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties
Key Takeaways Shifting to comprehensive, minimally invasive obesity solutions with device-plus-GLP-1 strategy supports stronger adoption, retention, and revenue growth opportunities worldwide. Streamlined operations and innovative product pipeline position the company for improved margins, cash flow, and long-term leadership as regulatory milestones approach.Read more
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$7
n/aintrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
24.63% p.a.
Profit Margin
12.35%
Future PE
21.8x
Share price in 2028
US$5.26
Global Obesity Trends And Telemedicine Will Accelerate Non-invasive Weight Loss
Key Takeaways Combination therapy and pipeline innovation position the company to become the leading non-invasive obesity solution with resilient, high-margin recurring revenues. Accelerated regulatory milestones and expanding global reimbursement could rapidly scale adoption, revenue diversification, and earnings beyond initial expectations.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$16
91.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
9.66% p.a.
Profit Margin
11.68%
Future PE
66.48x
Share price in 2028
US$11.96
Distributor Disruptions And FDA Delays Will Permit Modest Rebound
Key Takeaways Uncertainty from commercial strategy shifts, regulatory dependence, and operational risks threaten near-term revenue stability and sustainable top-line recovery despite favorable market trends. Success hinges on scaling digital platforms, expanding geographic access, and demonstrating product value, but execution missteps or competitive and reimbursement pressures could constrain margin growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2.5
44.4% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
3.25% p.a.
Profit Margin
11.68%
Future PE
12.45x
Share price in 2028
US$1.87
Recently Updated Narratives
AN
Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties
Fair Value: US$7 0% overvalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Distributor Disruptions And FDA Delays Will Permit Modest Rebound
Fair Value: US$2.5 44.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Global Obesity Trends And Telemedicine Will Accelerate Non-invasive Weight Loss
Fair Value: US$16 91.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Allurion Technologies Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -4.77
- 60.99%
- -297.99%
- -99.0%
About ALUR
- Founded
- n/a
- Employees
- 136
- CEO
- WebsiteView website
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
